Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States

Bradley J. Monk; Sophie van Mens; Oliver Hale; Jennifer Boer; Frank van Hees; Shilpi Swami; Dominic Muston; Cumhur Tekin; Steve Keefe; Matthew Monberg

doi:10.1007/s40487-024-00311-5

Back

Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States

Journal article

Open access

Peer reviewed

Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States

Bradley J. Monk, Sophie van Mens, Oliver Hale, Jennifer Boer, Frank van Hees, Shilpi Swami, Dominic Muston, Cumhur Tekin, Steve Keefe and Matthew Monberg

Oncology and therapy

11/05/2024

DOI: https://doi.org/10.1007/s40487-024-00311-5

Files and links (1)

url

https://doi.org/10.1007/s40487-024-00311-5View

Published (Version of record) Open

Metrics

1 Record Views

See more details

Details

Title: Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States
Creators: Bradley J. Monk - Creighton University
Sophie van Mens
Oliver Hale
Jennifer Boer
Frank van Hees
Shilpi Swami
Dominic Muston - MSD
Cumhur Tekin - MSD
Steve Keefe - MSD
Matthew Monberg - MSD
Publication Details: Oncology and therapy
Identifiers: 991006123172302656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article